Your Article Summary
See Latest ArticlesA phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites
Cancer Chemotherapy and Pharmacology, 07/03/08
Kuemmerle A et al. - Regional exposure to gemcitabine—the current standard drug for advanced adenocarcinoma of the pancreas—can be markedly enhanced using an optimised hypoxic stop-flow perfusion technique, with acceptable toxicities up to a dose of 1,125 mg/m^2. However, the activity of gemcitabine under hypoxic conditions is not as firmly established as that of other drugs such as mitomycin C, melphalan or tirapazamine. Further studies of this investigational modality, but with bioreductive drugs, are therefore warranted first to evaluate the tolerance in a phase I study and later on to assess whether it does improve the response to chemotherapy.
Related Articles
A Pilot Study for Combination Chemotherapy Using Gemcitabine and S-1 for Advanced Pancreatic Cancer
Oncology (Karger), 11/19/09
Relevance Score: 82%
In situ surgical procedures for locally advanced pancreatic cancer: partial abdominal evisceration and intestinal autotransplantation
Journal of Hepato-Biliary-Pancreatic Surgery, 11/12/09
Relevance Score: 81%
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09
Relevance Score: 81%
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
Journal of Clinical Oncology, 10/29/09
Relevance Score: 81%
Pancreatic Gout Masquerading as Pancreatic Cancer in a Heart Transplant Candidate
The Journal of Heart and Lung Transplantation, 10/07/09
Relevance Score: 81%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer
GlaxoSmithKline, 12/15/09
Targeting cancer with phosphodiesterase inhibitors
Expert Opinion on Investigational Drugs, 12/15/09
Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer
International Journal of Clinical Oncology, 12/15/09
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Safety of Oseltamivir Compared With the Adamantanes in Children Less Than 12 Months of Age
The Pediatric Infectious Disease Journal, 12/15/09
Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation
Pediatric Transplantation, 12/15/09
'Party pill' drugs - BZP and TFMPP
New Zealand Medical Journal, 12/14/09